These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20488404)

  • 1. Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies.
    Steinberg DH; Mintz GS; Mandinov L; Yu A; Ellis SG; Grube E; Dawkins KD; Ormiston J; Turco MA; Stone GW; Weissman NJ
    JACC Cardiovasc Interv; 2010 May; 3(5):486-94. PubMed ID: 20488404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved strut coverage and less late incomplete apposition with thin-strut TAXUS Liberté vs. TAXUS Express: the importance of stent platform design for drug-eluting stents.
    Weissman NJ; Turco MA; Ormiston JA; Mann T; Cannon LA; McGarry TF; Webster MW; Hall JJ; Lucca MJ; Mishkel GJ; Wu CJ; Mandinov L; Dawkins KD
    Cardiovasc Revasc Med; 2011; 12(4):247-57. PubMed ID: 21130708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials.
    Weissman NJ; Ellis SG; Grube E; Dawkins KD; Greenberg JD; Mann T; Cannon LA; Cambier PA; Fernandez S; Mintz GS; Mandinov L; Koglin J; Stone GW
    Eur Heart J; 2007 Jul; 28(13):1574-82. PubMed ID: 17540849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program.
    Turco MA; Ormiston JA; Popma JJ; Hall JJ; Mann T; Cannon LA; Webster MW; Mishkel GJ; O'Shaughnessy CD; McGarry TF; Mandinov L; Dawkins KD; Baim DS
    JACC Cardiovasc Interv; 2008 Dec; 1(6):699-709. PubMed ID: 19463387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program.
    Stone GW; Ellis SG; Colombo A; Grube E; Popma JJ; Uchida T; Bleuit JS; Dawkins KD; Russell ME
    JACC Cardiovasc Interv; 2011 May; 4(5):530-42. PubMed ID: 21596326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
    Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic arterial responses to overlapping paclitaxel-eluting stents: insights from serial intravascular ultrasound analyses in the TAXUS-V and -VI trials.
    Aoki J; Mintz GS; Weissman NJ; Mann JT; Cannon L; Greenberg J; Grube E; Masud AR; Koglin J; Mandinov L; Stone GW
    JACC Cardiovasc Interv; 2008 Apr; 1(2):161-7. PubMed ID: 19463294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
    Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
    Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
    Leon MB; Allocco DJ; Dawkins KD; Baim DS
    JACC Cardiovasc Interv; 2009 Jun; 2(6):504-12. PubMed ID: 19539253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent.
    Grube E; Schofer J; Hauptmann KE; Nickenig G; Curzen N; Allocco DJ; Dawkins KD
    JACC Cardiovasc Interv; 2010 Apr; 3(4):431-8. PubMed ID: 20398872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and long-term outcomes of ostial stentings among bare-metal stents, sirolimus-eluting stents, and paclitaxel-eluting stents.
    Hsieh IC; Hsieh MJ; Chang SH; Wang CY; Lee CH; Lin FC; Chen CC
    Coron Artery Dis; 2013 May; 24(3):224-30. PubMed ID: 23571311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of late-acquired incomplete stent apposition after drug-eluting stent versus bare-metal stent. A meta-analysis from 12 randomized trials.
    Sanchez-Recalde A; Moreno R; Barreales L; Rivero F; Galeote G; Jimenez-Valero S; Calvo L; López de Sá E; López-Sendón JL
    J Invasive Cardiol; 2008 Aug; 20(8):417-22. PubMed ID: 18688067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial.
    Tanabe K; Serruys PW; Degertekin M; Grube E; Guagliumi G; Urbaszek W; Bonnier J; Lablanche JM; Siminiak T; Nordrehaug J; Figulla H; Drzewiecki J; Banning A; Hauptmann K; Dudek D; Bruining N; Hamers R; Hoye A; Ligthart JM; Disco C; Koglin J; Russell ME; Colombo A;
    Circulation; 2005 Feb; 111(7):900-5. PubMed ID: 15710761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials.
    Hoffmann R; Morice MC; Moses JW; Fitzgerald PJ; Mauri L; Breithardt G; Schofer J; Serruys PW; Stoll HP; Leon MB
    Heart; 2008 Mar; 94(3):322-8. PubMed ID: 17761505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final 5-year results of the TAXUS ATLAS, TAXUS ATLAS Small Vessel, and TAXUS ATLAS Long Lesion clinical trials of the TAXUS Liberté paclitaxel-eluting stent in de-novo coronary artery lesions.
    Ormiston JA; Charles O; Mann T; Hall JJ; McGarry T; Cannon LA; Webster MW; Mishkel GJ; Underwood PL; Dawkins KD
    Coron Artery Dis; 2013 Jan; 24(1):61-8. PubMed ID: 23232250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
    Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
    JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of the platinum chromium TAXUS Element (ION) stent: The PERSEUS Workhorse and Small Vessel trial five-year results.
    Kereiakes DJ; Cannon LA; Dauber I; Ball M; Bertolet B; Foster M; Nersesov AY; Underwood PL; Allocco DJ; Dawkins KD
    Catheter Cardiovasc Interv; 2015 Nov; 86(6):994-1001. PubMed ID: 25678402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.